176 related articles for article (PubMed ID: 38558529)
1. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.
Jia W; Yao Q; Wang Y; Mao Z; Zhang T; Li J; Nie Y; Lei X; Shi W; Song W
Front Immunol; 2022; 13():1007426. PubMed ID: 36189217
[TBL] [Abstract][Full Text] [Related]
3. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
4. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Jamaly S; Berg T; Paulsen EE; Berglund M; Richardsen E; Andersen S; Al-Saad S; Poehl M; Pezzella F; Kwiatkowski DJ; Bremnes RM; Busund LR; Donnem T
Br J Cancer; 2021 May; 124(10):1680-1689. PubMed ID: 33723388
[TBL] [Abstract][Full Text] [Related]
5. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
Xiaoxu D; Min X; Chengcheng C
BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
[TBL] [Abstract][Full Text] [Related]
6. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.
Wakasu S; Tagawa T; Haratake N; Kinoshita F; Oku Y; Ono Y; Takenaka T; Oda Y; Shimokawa M; Mori M
Cancer Immunol Immunother; 2023 Jun; 72(6):1823-1834. PubMed ID: 36688996
[TBL] [Abstract][Full Text] [Related]
8. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
Yao Y; Xuan H; Wang J; Gong L; Gao W
Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
[TBL] [Abstract][Full Text] [Related]
10. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
11. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
Liu Z; Meng X; Tang X; Zou W; He Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
[TBL] [Abstract][Full Text] [Related]
15. Identifying specific TLS-associated genes as potential biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in soft tissue sarcoma.
Wang XX; Liu YP; Lu Y; Wu LH; Ren JY; Ji H; Wang X; Zhang HM
Front Immunol; 2024; 15():1372692. PubMed ID: 38720884
[TBL] [Abstract][Full Text] [Related]
16. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
Wang B; Liu J; Han Y; Deng Y; Li J; Jiang Y
Front Immunol; 2022; 13():868155. PubMed ID: 35664009
[TBL] [Abstract][Full Text] [Related]
17. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
18. [Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer].
Liu Y; Xiong L; Cai R; Chen Y; Ye J; Shen B; Zhou G
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):615-620. PubMed ID: 37752541
[TBL] [Abstract][Full Text] [Related]
19. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
20. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma.
Wang D; Huang L; Qian D; Cao Y; Wu X; Xu P; Ming L; Tang J; Huang Z; Yin Y; Zhou L
Front Immunol; 2023; 14():1334408. PubMed ID: 38259481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
